Tiotropium: a potential replacement for ipratropium in patients with COPD
Shukla V K
Record ID 32002000474
English, French
Authors' objectives:
To summarise the available evidence on tiotropium as a potential replacement for ipratropium in patients with chronic obstructive pulmonary disease.
Authors' recommendations:
- Inhaled tiotropium provides a sustained bronchodilator effect over a 24-hour period in patients with chronic obstructive pulmonary disease (COPD).
- There is some evidence that tiotropium 18g once daily is more efficacious than ipratropium bromide 40 g four times daily, for patients with COPD, as measured by improvements in lung function, dyspnea disease-specific quality of life and reductions in hospitalization due to COPD.
- Dry mouth is a more frequent problem with tiotropium than with ipratropium bromide.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bronchodilator Agents
- Scopolamine Derivatives
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.